DRIOW - (DarioHealth Corp.)

 DRIOWのチャート


 DRIOWの企業情報

symbol DRIOW
会社名
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種   
概要 事業概要 --     DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. Its solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in Caesarea, Israel.
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear ―年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/driow
adr_tso
EBITDA EBITDA ー
終値(lastsale) 0.14
時価総額(marketcap) 0
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 DRIOWのテクニカル分析


 DRIOWのニュース

   Dennis Matheis, President of Optima Health, a Multi-line Health Plan With More Than 850,000 Members and over 26,000 Providers, and Former President of Anthem Blue Cross and Blue Shield Central Region, Appointed to the Board of DarioHealth Corp  2020/07/06 12:30:00 PR Newswire
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has appointed veteran…
   Dario Health to Host Key Opinion Leader Call on Digital Therapeutics for the Management of Diabetes and Other Chronic Conditions  2020/06/18 12:30:00 PR Newswire
NEW YORK, June 18, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it will host a key opinion leader (KOL) call on digital therapeutics for the management of diabetes and other chronic conditions on Tuesday,…
   DarioHealth Announces Participation in the Virtual Going Digital: Behavioral Health Tech Summit  2020/06/17 12:30:00 PR Newswire
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that Omar Manejwala, M.D., Chief Medical…
   DarioHealth Presents New Studies Demonstrating Sustained Improvements in Blood Glucose and Blood Pressure Control in Users with Diabetes and Hypertension at the American Diabetes Association's 80th Scientific Sessions  2020/06/15 12:30:00 PR Newswire
NEW YORK, June 15, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) company, presented the results of two new studies at the American Diabetes Association's (ADA) 80th Scientific Sessions that showed sustained improvements in blood glucose…
   DarioHealth Announces Two Remote Patient Monitoring (RPM) Agreements and Commences Enrollment  2020/06/11 12:30:00 PR Newswire
NEW YORK, June 11, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has signed its first two remote patient monitoring (RPM) agreements. Remote patient monitoring will allow treating physicians to…
   Dario Health to Host Key Opinion Leader Call on Digital Therapeutics for the Management of Diabetes and Other Chronic Conditions  2020/06/18 12:30:00 PR Newswire
NEW YORK, June 18, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it will host a key opinion leader (KOL) call on digital therapeutics for the management of diabetes and other chronic conditions on Tuesday,…
   DarioHealth Announces Participation in the Virtual Going Digital: Behavioral Health Tech Summit  2020/06/17 12:30:00 PR Newswire
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that Omar Manejwala, M.D., Chief Medical…
   DarioHealth Presents New Studies Demonstrating Sustained Improvements in Blood Glucose and Blood Pressure Control in Users with Diabetes and Hypertension at the American Diabetes Association's 80th Scientific Sessions  2020/06/15 12:30:00 PR Newswire
NEW YORK, June 15, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) company, presented the results of two new studies at the American Diabetes Association's (ADA) 80th Scientific Sessions that showed sustained improvements in blood glucose…
   DarioHealth Announces Two Remote Patient Monitoring (RPM) Agreements and Commences Enrollment  2020/06/11 12:30:00 PR Newswire
NEW YORK, June 11, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has signed its first two remote patient monitoring (RPM) agreements. Remote patient monitoring will allow treating physicians to…
   THE DIGITAL THERAPEUTICS EXPLAINER: How digital treatments could be a $9 billion opportunity by 2025  2020/06/06 20:02:00 Business Insider
This is a preview of The Digital Therapeutics research report from Business Insider Intelligence. Purchase this report. Business Insider Intelligence offers even more healthcare coverage with Digital Health Pro. Subscribe today to receive industry-changing digital health news and analysis to your inbox. A new class of medicine — digital therapeutics (DTx) — has emerged, offering a novel means of treating the swelling number of patients with chronic diseases and keeping associated costs down. Digital therapeutics deliver evidence-based therapies via software — often in the form of consumer-facing mobile health apps — that replace or complement the existing treatment of a disease. They diverge from the broader digital health market in that they must be approved by regulatory bodies — and displaying proof-of-concept is at the core of their model. DTx vendors leverage their tech to treat chronic conditions, which gobble up the lion's share of the US' healthcare spending: Business Insider Intelligence estimates that the US shelled out up to $3.3 trillion on chronic disease in 2018.
   Dario Health to Host Key Opinion Leader Call on Digital Therapeutics for the Management of Diabetes and Other Chronic Conditions  2020/06/18 12:30:00 PR Newswire
NEW YORK, June 18, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it will host a key opinion leader (KOL) call on digital therapeutics for the management of diabetes and other chronic conditions on Tuesday,…
   DarioHealth Announces Participation in the Virtual Going Digital: Behavioral Health Tech Summit  2020/06/17 12:30:00 PR Newswire
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that Omar Manejwala, M.D., Chief Medical…
   DarioHealth Presents New Studies Demonstrating Sustained Improvements in Blood Glucose and Blood Pressure Control in Users with Diabetes and Hypertension at the American Diabetes Association's 80th Scientific Sessions  2020/06/15 12:30:00 PR Newswire
NEW YORK, June 15, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) company, presented the results of two new studies at the American Diabetes Association's (ADA) 80th Scientific Sessions that showed sustained improvements in blood glucose…
   DarioHealth Announces Two Remote Patient Monitoring (RPM) Agreements and Commences Enrollment  2020/06/11 12:30:00 PR Newswire
NEW YORK, June 11, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has signed its first two remote patient monitoring (RPM) agreements. Remote patient monitoring will allow treating physicians to…
   THE DIGITAL THERAPEUTICS EXPLAINER: How digital treatments could be a $9 billion opportunity by 2025  2020/06/06 20:02:00 Business Insider
This is a preview of The Digital Therapeutics research report from Business Insider Intelligence. Purchase this report. Business Insider Intelligence offers even more healthcare coverage with Digital Health Pro. Subscribe today to receive industry-changing digital health news and analysis to your inbox. A new class of medicine — digital therapeutics (DTx) — has emerged, offering a novel means of treating the swelling number of patients with chronic diseases and keeping associated costs down. Digital therapeutics deliver evidence-based therapies via software — often in the form of consumer-facing mobile health apps — that replace or complement the existing treatment of a disease. They diverge from the broader digital health market in that they must be approved by regulatory bodies — and displaying proof-of-concept is at the core of their model. DTx vendors leverage their tech to treat chronic conditions, which gobble up the lion's share of the US' healthcare spending: Business Insider Intelligence estimates that the US shelled out up to $3.3 trillion on chronic disease in 2018.

 関連キーワード  (― 米国株 DRIOW DarioHealth Corp.)

 twitter  (公式ツイッターやCEOツイッターなど)